U.S. Cardiac Resynchronization Therapy Market Key Indicators, Industry Competitor along with Major Industry Players by 2027

Share this news:

Rise in geriatric population, increase in prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market.

As per the report published by Allied Market Research, the U.S. Cardiac Resynchronization Therapy Market was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/10657

The presence of favorable reimbursement policies, rise in investments, increase in technological advancements, and a growth in sedentary lifestyle among the U.S. population makes way for the growth of the cardiac resynchronization therapy market in the U.S. In addition, U.S. healthcare spending grew 4.6% in 2019 (as compared to 2018), reaching $3.8 trillion or $11,582 per person is expected to assist in the market growth over the forecast period.

Rise in geriatric population, increase in prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. However, the hospitals segment held the largest share in 2019, accounting for more than three-fifths of the market. The integration of CRT pacemaker and cardiac resynchronization therapy defibrillator significantly reduced during the Covid-19 pandemic.

Enquiry for Short-term and Long-term Impacts of COVID-19 at: https://www.alliedmarketresearch.com/purchase-enquiry/10657

Based on end user, the specialized cardiac treatment centers segment is estimated to register the highest CAGR of 6.0% during the forecast period. However, the hospitals segment held the largest share in 2019, accounting for more than three-fifths of the market.

Key Findings Of The Study

On the basis of type, the CRT defibrillator segment was the highest contributor to the U.S. cardiac resynchronization therapy market in 2019.

On the basis of application, the intraventricular dyssynchrony segment dominated the U.S. cardiac resynchronization therapy market in 2019, and is expected to continue this trend during the forecast period.

On the basis of end user, the specialized cardiac treatment centers segment is anticipated to register fastest CAGR during the forecast period.

The U.S. cardiac resynchronization therapy market report includes an in-depth analysis of the major market players such as Abbott Laboratories, Osypka Medical GmbH, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Medtronic plc, LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Lepu Medical Technology (Beijing) Co., Ltd.

Read More: https://www.alliedmarketresearch.com/us-cardiac-resynchronization-therapy-market-A10292

Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Address: 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States
Phone: 1-800-792-5285
Website: https://www.alliedmarketresearch.com/

Release ID: 89032605

CONTACT ISSUER
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Address: 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States
SUBSCRIBE FOR MORE